Neurologie up2date, Table of Contents Neurologie up2date 2022; 05(03): 233-250DOI: 10.1055/a-1761-4134 Zerebrovaskuläre Erkrankungen Intrazerebrale Blutungen Christian Weimar , Götz Thomalla , I. Erol Sandalcioglu Recommend Article Abstract Buy Article All articles of this category Intrazerebrale Blutungen (ICB) verursachen ca. 12% aller Schlaganfälle in Deutschland und 9–27% aller Schlaganfälle weltweit [1], [2]. In epidemiologischen Studien zeigen sich eine Abnahme bei jüngeren Personen vor allem aufgrund besserer antihypertensiver Einstellung, es ist jedoch auch eine Zunahme der Inzidenz bei älteren Personen aufgrund einer zerebralen Amyloidangiopathie und des zunehmenden Einsatzes von Antikoagulanzien zu verzeichnen [3]. Full Text References Literatur 1 Eyding J, Bartig D, Weber R. et al. Inpatient TIA and stroke care in adult patients in Germany - retrospective analysis of nationwide administrative data sets of 2011 to 2017. Neurol Res Pract 2019; 1: 39 2 Feigin VL, Lawes CM, Bennett DA. et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8: 355-369 3 Jolink WM, Klijn CJ, Brouwers PJ. et al. Time trends in incidence, case fatality, and mortality of intracerebral hemorrhage. Neurology 2015; 85: 1318-1324 4 Poon MT, Bell SM, Al-Shahi Salman R. Epidemiology of intracerebral haemorrhage. Front Neurol Neurosci 2015; 37: 1-12 5 Rost NS, Greenberg SM, Rosand J. The genetic architecture of intracerebral hemorrhage. Stroke 2008; 39: 2166-2173 6 Garcia JH, Ho KL. Pathology of hypertensive arteriopathy. Neurosurg Clin N Am 1992; 3: 497-507 7 Al-Shahi Salman R, Frantzias J, Lee RJ. et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurol 2018; 17: 885-894 8 AWMF-Leitlinienregister 030/002. Behandlung von spontanen intrazerebralen Blutungen, gültig bis 31.03.2024. https://www.awmf.org/leitlinien/detail/ll/030-002.html 9 Christensen H, Cordonnier C, Korv J. et al. European stroke organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. Eur Stroke J 2019; 4: 294-306 10 Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005; 36: 1588-1593 11 Schols AM, Schreuder FH, van Raak EP. et al. Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands. Stroke 2014; 45: 268-270 12 Rosand J, Eckman MH, Knudsen KA. et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164: 880-884 13 Caldeira D, Barra M, Pinto FJ. et al. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol 2015; 262: 516-522 14 Pollack Jr CV, Reilly PA, Weitz JI. Dabigatran reversal with idarucizumab. N Engl J Med 2017; 377: 1691-1692 15 Connolly SJ, Crowther M, Eikelboom JW. et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380: 1326-1335 16 Anderson CS, Heeley E, Huang Y. et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355-2365 17 Qureshi AI, Palesch YY, Barsan WG. et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016; 375: 1033-1043 18 Boulouis G, Morotti A, Goldstein JN. et al. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials. J Neurol Neurosurg Psychiatry 2017; 88: 339-345 19 Li Q, Warren AD, Qureshi AI. et al. Ultra-early blood pressure reduction attenuates hematoma growth and improves outcome in intracerebral hemorrhage. Ann Neurol 2020; 88: 388-395 20 Burgess LG, Goyal N, Jones GM. et al. Evaluation of acute kidney injury and mortality after intensive blood pressure control in patients with intracerebral hemorrhage. J Am Heart Assoc 2018; 7: e008439 21 Sprigg N, Flaherty K, Appleton JP. et al. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet 2018; 391: 2107-2115 22 Mendelow A, Gregson B, Fernandes H. et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365: 387-397 23 Mendelow AD, Gregson BA, Rowan EN. et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013; 382: 397-408 24 Sondag L, Schreuder F, Boogaarts HD. et al. Neurosurgical intervention for supratentorial intracerebral hemorrhage. Ann Neurol 2020; 88: 239-250 25 Hanley DF, Thompson RE, Muschelli J. et al. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. Lancet Neurol 2016; 15: 1228-1237 26 Hanley DF, Thompson RE, Rosenblum M. et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet 2019; 393: 1021-1032 27 Kuramatsu JB, Biffi A, Gerner ST. et al. Association of surgical hematoma evacuation vs conservative treatment with functional outcome in patients with cerebellar intracerebral hemorrhage. JAMA 2019; 322: 1392-1403 28 Feigin VL, Anderson N, Rinkel GJ. et al. Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage. Cochrane Database Syst Rev 2005; 3: CD004583 29 Hanley DF, Lane K, McBee N. et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet 2017; 389: 603-611 30 Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2014; 85: 660-667 31 Hemphill JC, Bonovich DC, Besmertis L. et al. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001; 32: 891-897 32 Weimar C, Benemann J, Diener HC. Development and validation of the Essen Intracerebral Haemorrhage Score. J Neurol Neurosurg Psychiatry 2006; 77: 601-605 33 Murthy SB, Zhang C, Diaz I. et al. Association between intracerebral hemorrhage and subsequent arterial ischemic events in participants from 4 population-based cohort studies. JAMA Neurol 2021; 78: 809-816 34 Dennis M, Sandercock P. Clots Trials Collaboration. et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 2013; 382: 516-524 35 Ottosen TP, Grijota M, Hansen ML. et al. Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage. Stroke 2016; 47: 1837-1843 36 Casolla B, Moulin S, Kyheng M. et al. Five-year risk of major ischemic and hemorrhagic events after intracerebral hemorrhage. Stroke 2019; 50: 1100-1107 37 Restart Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet 2019; 393: 2613-2623 38 Chao TF, Liu CJ, Liao JN. et al. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016; 133: 1540-1547 39 Kubiszewski P, Sugita L, Kourkoulis C. et al. Association of selective serotonin reuptake inhibitor use after intracerebral hemorrhage with hemorrhage recurrence and depression severity. JAMA Neurol 2020; 78: 1-8
